TREDAPTIVETM (Nicotinic Acid /Laropiprant) Approved In The European Union: New Lipid-Modifying Therapy To Treat LDL-C, HDL-C And Triglycerides

July 14th, 2008 | Category: Cholesterol

Merck Sharp & Dohme (MSD) announced that TREDAPTIVE™ (nicotinic acid/laropiprant, MSD) 1 g/20 mg modified-release tablets, a new lipid-modifying therapy for patients with dyslipidemia and primary hypercholesterolemia, has been approved for marketing in

the European Union (EU), Iceland and Norway. TREDAPTIVE combines nicotinic acid (niacin) and laropiprant, a novel flushing pathway inhibitor.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Two Merck Medicines Recommended For Approval In The European Union
  • Expanded Labelling For Januvia(R) (Sitagliptin) Approved By European Commission
  • Tredaptive Recommended For EU Approval For The Treatment Of Mixed Dyslipidaemia And Primary Hypercholesterolaemia
  • Aclasta(R) Receives European Approval As First Once-yearly Treatment For Postmenopausal Osteoporosis
  • Aclasta Receives European Approval As First Once Yearly Treatment For Postmenopausal Osteoporosis

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.